Skip to main content
Trending
Corporate earningsAi infrastructureEnergy marketsElection litigationAviation safetyCrypto securityAi governanceEnterprise aiPlatform liabilityAvian influenzaClinical trialsFederal debtPresidential runoffRpg developmentSpace debrisAir defenseAutonomous vehiclesBudget crisisBug bountiesEnergy m&aForeign investmentFranchise restructuringGene therapyPandemic treatyTranslation pathwaysUn peacekeepingWeapons testingWeight-space programmingAi copyright lawArchaeological toxicology

full timeline

Tarlatamab and Durvalumab Combination Achieves Overall Survival Benefit in First-Line Extensive-Stage Small Cell Lung Cancer

A novel bispecific T-cell engager has shattered historical survival barriers for one of the most aggressive forms of lung cancer. By bridging immune cells directly to tumors, the dual-drug regimen nearly doubles life expectancy for patients following initial chemotherapy.

Factlen Newsroom· Updated

Follow Tarlatamab and Durvalumab Combination Achieves Overall Survival Benefit in First-Line Extensive-Stage Small Cell Lung Cancer in the Factlen app and get an alert when there is news. Get the app

Illustration: The DeLLphi-305 trial results establish a new standard of care for extensive-stage small cell lung cancer.From: Tarlatamab Maintenance Doubles Survival Time in Extensive-Stage Small Cell Lung Cancer

Share this story

Charts, maps and images

Adding tarlatamab to durvalumab maintenance extended median overall survival by more than eight months.From: Tarlatamab Maintenance Doubles Survival Time in Extensive-Stage Small Cell Lung Cancer ·
Progression-free survival more than tripled with the dual-drug regimen.From: Tarlatamab Maintenance Doubles Survival Time in Extensive-Stage Small Cell Lung Cancer ·
Mechanism of a bispecific T-cell engager bridging an immune cell to a tumor cell.From: Tarlatamab and Durvalumab Combination Achieves Overall Survival Benefit in First-Line Extensive-Stage Small Cell Lung Cancer ·
Historical survival timelines in extensive-stage small cell lung cancer.From: Tarlatamab and Durvalumab Combination Achieves Overall Survival Benefit in First-Line Extensive-Stage Small Cell Lung Cancer ·
Illustration: Clinicians are now preparing to integrate bispecific T-cell engagers into earlier lines of lung cancer treatment.From: Tarlatamab Maintenance Doubles Survival Time in Extensive-Stage Small Cell Lung Cancer ·

Timeline

October 2026

  1. Tarlatamab Maintenance Doubles Survival Time in Extensive-Stage Small Cell Lung Cancer

September 2026

  1. Tarlatamab and Durvalumab Combination Achieves Overall Survival Benefit in First-Line Extensive-Stage Small Cell Lung Cancer